BAM

Testing for Bile Acid Malabsorption When IBS Treatment Is Not Working

April 25, 202612 min readBy GLP1Gut Team
bile acid malabsorptionBAM testingSeHCATserum C4cholestyramine

📋TL;DR: If IBS-D treatments are not working, BAM testing should be the next step. SeHCAT is the gold standard (available in the UK and Europe), with cutoffs at 15%, 10%, and 5% indicating mild, moderate, and severe BAM. In the US, serum C4 blood testing or a therapeutic trial of cholestyramine (4 to 16 grams per day) or colesevelam (625 mg tablets) are the main alternatives. Response rates to sequestrants exceed 70 percent.

What We Know

  • SeHCAT retention below 15 percent at 7 days is diagnostic of BAM, with severity graded at below 10 percent (moderate) and below 5 percent (severe) (Merrick et al., 2012).
  • Serum C4 (7-alpha-hydroxy-4-cholesten-3-one) above 52.5 nanograms per milliliter has approximately 90 percent sensitivity for BAM when SeHCAT is used as the reference standard (Brydon et al., 1996).
  • Cholestyramine at 4 to 16 grams per day and colesevelam at 625 mg two to three tablets twice daily are the primary treatment options (Walters, 2014).
  • A therapeutic trial of bile acid sequestrants is a validated diagnostic strategy when formal testing is unavailable (Camilleri, 2020).
  • Response to sequestrants occurs within days to 2 weeks in most patients with confirmed BAM (Wedlake et al., 2009).

What We Don't Know

  • Whether newer biomarkers such as fasting serum FGF19 will replace SeHCAT and C4 as the primary diagnostic tools.
  • The optimal duration of a therapeutic trial before concluding that the patient does not have BAM.
  • Whether serum C4 cutoffs validated in European populations apply equally to other populations.
  • How to reliably diagnose mild BAM (SeHCAT 10 to 15 percent range) when only C4 or therapeutic trials are available.
  • Whether fecal bile acid testing will become a practical clinical tool or remain primarily a research method.

When standard IBS-D treatments are not controlling your symptoms, bile acid malabsorption should be one of the first conditions your doctor investigates. BAM affects 25 to 30 percent of IBS-D patients and responds to specific treatment with bile acid sequestrants in over 70 percent of cases. This article covers the three main diagnostic approaches: SeHCAT scanning, serum C4 blood testing, and therapeutic trials of bile acid sequestrants. It includes the numbers you need: test cutoffs, medication dosing, and what a meaningful response looks like.

When Should You Ask for BAM Testing?

Consider BAM testing if you meet any of the following criteria. You have been diagnosed with IBS-D and have not responded adequately to dietary changes (including low-FODMAP), antispasmodics, or other standard IBS therapies after a reasonable trial period of 8 to 12 weeks. Your diarrhea consistently worsens after fatty meals. You have severe morning diarrhea, often with multiple urgent episodes before midday. You developed chronic diarrhea after gallbladder removal. You have Crohn's disease affecting the ileum or have had ileal resection surgery. Your stools are watery rather than just loose, and urgency is a dominant feature. You do not need to meet all of these criteria. Any one of them, combined with inadequate response to IBS treatment, is sufficient reason to pursue testing.

Test 1: SeHCAT Scan (Gold Standard)

SeHCAT (selenium-75-homocholic acid taurine) is a nuclear medicine test that directly measures how well your body retains bile acids. You swallow a capsule containing a small amount of a radiolabeled synthetic bile acid. A gamma camera takes an initial reading of the radioactivity in your abdomen. You return 7 days later for a second reading. The percentage retained at day 7, compared to day 1, is your SeHCAT retention value.

How to Interpret SeHCAT Results

SeHCAT Retention at Day 7InterpretationClinical Significance
Above 15%NormalBAM is unlikely to be the primary cause of symptoms
10% to 15%Mild BAMMay contribute to symptoms, particularly in combination with other factors. A trial of sequestrants is reasonable.
5% to 10%Moderate BAMLikely a significant contributor to diarrhea. Sequestrant treatment is recommended.
Below 5%Severe BAMStrongly indicates BAM as the primary cause of diarrhea. Sequestrant treatment should be initiated.

The test is non-invasive, involves minimal radiation exposure (less than a standard CT scan), and has high diagnostic accuracy. The main limitation is availability: SeHCAT is approved and widely used in the UK and several European countries but is not available in the United States, Canada, Australia, or most of Asia. If you are in a country where SeHCAT is available, this should be the first test your doctor orders when BAM is suspected.

Test 2: Serum C4 (7-alpha-hydroxy-4-cholesten-3-one)

Serum C4 is a blood test that measures a bile acid synthesis intermediate. When your body loses excess bile acids (as in BAM), the liver compensates by increasing bile acid production. C4 is a precursor in this production pathway, so elevated C4 levels indicate increased bile acid synthesis, which is a surrogate marker for BAM. The test requires a fasting blood draw, ideally taken in the morning, as C4 levels have a diurnal variation pattern.

How to Interpret C4 Results

Reference ranges vary between laboratories, but the commonly used cutoff derived from validation studies against SeHCAT is 52.5 nanograms per milliliter. Values above this threshold suggest BAM with approximately 90 percent sensitivity and 79 percent specificity for moderate to severe BAM (SeHCAT below 10 percent). Sensitivity is lower for mild BAM (SeHCAT 10 to 15 percent range). Important caveats: statins can lower C4 levels and produce false-negative results, so the test should be interpreted cautiously in patients taking statins. Liver disease can also affect C4 metabolism. Fasting and morning sampling improve reliability. Despite these limitations, serum C4 is the most practical blood-based test for BAM and is available through major reference laboratories in the United States.

Test 3: Therapeutic Trial of Bile Acid Sequestrants

When neither SeHCAT nor C4 is readily available, or when a clinician wants to combine diagnosis with treatment, a therapeutic trial of a bile acid sequestrant is a well-accepted approach. The logic is straightforward: if the patient's diarrhea improves significantly on a bile acid sequestrant, that response is itself evidence of BAM. This approach is endorsed by multiple gastroenterology guidelines, including the British Society of Gastroenterology and the American Gastroenterological Association. It is not a second-rate option. In practice, many gastroenterologists prefer it because it answers the diagnostic question and begins treatment simultaneously.

Cholestyramine (Questran): Dosing and Practical Tips

Cholestyramine is the oldest and most studied bile acid sequestrant. It comes as a powder that is mixed with water or juice. The standard dosing schedule starts at 4 grams once daily, taken before the largest meal. If tolerated, the dose is increased to 4 grams twice daily after one week, and then to 4 grams three times daily if needed. The maximum dose is 16 grams per day (4 grams four times daily), though most patients find their effective dose between 4 and 12 grams daily. Practical considerations: cholestyramine has a gritty, sometimes unpleasant texture that is the most common reason patients discontinue it. Mixing with a small volume of cold juice (apple or orange) and letting it sit for a few minutes before drinking can improve palatability. It must be taken at least 1 hour before or 4 hours after other medications, as it can bind and reduce absorption of many drugs including thyroid hormones, warfarin, and oral contraceptives. Common side effects include constipation (which can actually be therapeutic in the context of diarrhea), bloating, and nausea. Starting at a low dose and titrating slowly minimizes these effects.

Colesevelam (Welchol): Dosing and Practical Tips

Colesevelam is a newer bile acid sequestrant available in tablet form, which eliminates the palatability issues of cholestyramine. Each tablet is 625 milligrams. The typical starting dose is 1 tablet (625 mg) twice daily with meals, increasing to 2 to 3 tablets twice daily as needed. The maximum recommended dose is 3.75 grams per day (six 625 mg tablets). Colesevelam has fewer drug interactions than cholestyramine and is generally better tolerated. It does not need to be separated from other medications by as large a window, though taking it at least 4 hours apart from thyroid hormones and certain other drugs is still advised. The main drawback is cost: colesevelam is significantly more expensive than cholestyramine, and insurance coverage varies. For patients who cannot tolerate cholestyramine, colesevelam is the preferred alternative.

Colestipol: A Third Option

Colestipol is a third bile acid sequestrant that is used less frequently but remains an option. It is available in both tablet and granule form. Dosing typically starts at 2 grams twice daily, with a maximum of 16 grams per day. Its drug interaction profile is similar to cholestyramine. Colestipol is sometimes tried when a patient does not tolerate either cholestyramine or colesevelam.

What Does a Meaningful Response Look Like?

When BAM is the cause of diarrhea, patients typically notice improvement within the first 3 to 7 days of starting a bile acid sequestrant. Some respond within 48 hours. A meaningful response includes a reduction in daily stool frequency (for example, from 5 to 6 episodes per day down to 1 to 2), a change from watery to formed stools, reduced urgency, and less post-meal diarrhea. The response does not need to be complete at the starting dose. Many patients achieve partial improvement at 4 grams of cholestyramine and full symptom control at 8 to 12 grams. The GLP1Gut app can help you track stool frequency, consistency, and urgency day by day during a treatment trial, giving you and your doctor clear data on whether the response is real and dose-dependent.

If there is no improvement after 2 weeks at an adequate dose (at least 8 grams of cholestyramine daily or 2.5 grams of colesevelam daily), BAM is less likely to be the primary cause of symptoms. However, inadequate dosing is a common reason for apparent treatment failure. Ensure the dose has been properly titrated before concluding the trial is negative.

What to Expect During the First Weeks of Treatment

The first few days of a bile acid sequestrant can be an adjustment period. Some patients experience increased bloating or mild constipation as the medication binds bile acids that were previously stimulating their colon. This is actually a sign the medication is working. If constipation becomes uncomfortable, reduce the dose slightly and increase more gradually. Timing matters. Taking the sequestrant 15 to 30 minutes before meals gives it time to be present in the small intestine when bile acids are released. Some patients find that taking the largest dose before their fattiest meal of the day produces the best results. If you take other medications, plan the timing carefully. A simple schedule might be: take the sequestrant 30 minutes before breakfast, take other medications at lunch (at least 4 hours later), and take a second sequestrant dose 30 minutes before dinner.

Other Tests You May Encounter

Several other BAM-related tests exist but are less commonly used in clinical practice. Fasting serum FGF19 is a research tool that measures the hormone involved in bile acid feedback regulation. Low FGF19 levels support a diagnosis of Type 2 BAM but the test is not standardized for clinical use. Fecal bile acid measurement (48-hour stool collection) directly quantifies bile acids in the stool. Values above 2,337 micromoles per 48 hours are considered elevated. This test is accurate but cumbersome and rarely ordered outside of research settings. A 48-hour stool collection is, understandably, not popular with patients. Your clinician may also order a fecal elastase-1 test to rule out pancreatic exocrine insufficiency, or celiac serology to exclude celiac disease, both of which can cause similar symptoms and should be excluded before attributing diarrhea to BAM.

Talking to Your Doctor: What to Say

If you want to raise BAM testing with your gastroenterologist, here is a direct approach. Describe your symptoms specifically: how many times per day you are having diarrhea, whether it worsens after fatty meals, whether mornings are the worst, and how long this has been going on. Mention that your current IBS treatments have not produced adequate improvement. Then ask directly: 'Could this be bile acid malabsorption? I have read that it affects 25 to 30 percent of IBS-D patients. Can we do a serum C4 test or try a bile acid sequestrant?' Most gastroenterologists will be receptive to this request, particularly if you can articulate why your symptoms fit the BAM profile. If your clinician is unfamiliar with BAM testing, the Wedlake 2009 systematic review and the BSG 2021 IBS guidelines are good references to share.

How long should I try a bile acid sequestrant before deciding it is not working?

Give it at least 2 weeks at an adequate dose. Start at 4 grams of cholestyramine daily for the first week, then increase to 8 grams daily for the second week. If there is no improvement at all after 2 weeks at 8 grams, BAM is less likely to be your primary issue. However, some patients with mild BAM only respond at higher doses (12 to 16 grams), so discuss further titration with your doctor before abandoning the trial entirely. For colesevelam, a trial of 2 tablets (1,250 mg) twice daily for 2 weeks is a reasonable minimum.

Can I take a bile acid sequestrant long-term?

Yes. Bile acid sequestrants have been used for decades, originally for cholesterol lowering, and have a well-established long-term safety profile. The main consideration is monitoring fat-soluble vitamin levels (A, D, E, K) annually, as sequestrants can reduce absorption of these vitamins over time. Many BAM patients take sequestrants for years or indefinitely with good effect. Your doctor may also check cholesterol levels periodically, though for most patients the sequestrants have a beneficial effect on LDL cholesterol.

What if I respond to the sequestrant but cannot tolerate the side effects?

The most common side effects are constipation, bloating, and nausea with cholestyramine, plus the unpleasant taste and texture. If cholestyramine is effective but intolerable, switch to colesevelam tablets. If bloating is the issue, try a lower dose and titrate more slowly. Some patients do well splitting their dose into smaller amounts taken before each meal rather than larger doses twice daily. Colestipol is a third option if neither cholestyramine nor colesevelam works for you.

Does the serum C4 test require any special preparation?

Yes. The blood should be drawn fasting, ideally in the morning before 10 AM, because C4 levels follow a diurnal pattern and are highest in the morning. Stop statin medications for at least 2 weeks before the test if your doctor agrees this is safe, as statins can lower C4 levels and cause a false-negative result. Inform the lab or your doctor if you have liver disease, as this can also affect C4 metabolism. Otherwise, no special diet or preparation is needed.

Will my insurance cover BAM testing and treatment?

Serum C4 is a standard laboratory test covered by most insurance plans when ordered with an appropriate diagnosis code (chronic diarrhea, IBS-D). Cholestyramine is a generic medication that is inexpensive and widely covered. Colesevelam is more expensive, and coverage varies by plan; your doctor may need to document failure of cholestyramine (or intolerance) to get colesevelam approved. SeHCAT is covered by the NHS in the UK. In the US, since SeHCAT is unavailable, insurance coverage is not applicable for that test.

â„šī¸This article is for informational purposes only and does not constitute medical advice. Medication dosing information is provided for educational context. Always consult your healthcare provider before starting, stopping, or changing any medication. Chronic diarrhea has many potential causes and requires proper medical evaluation.

Key Takeaways

  1. 1SeHCAT is the most accurate BAM test but is only available in the UK and parts of Europe.
  2. 2Serum C4 is the best available blood test in the US, with good sensitivity for moderate to severe BAM.
  3. 3A therapeutic trial of a bile acid sequestrant is a practical and widely accepted diagnostic approach.
  4. 4Start cholestyramine at 4 grams daily and titrate up gradually to minimize side effects.
  5. 5Track symptoms carefully during a treatment trial to determine whether the response is clinically meaningful.

Sources & References

  1. 1.Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome - Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ, Alimentary Pharmacology & Therapeutics (2009)
  2. 2.Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea - Brydon WG, Nyhlin H, Eastwood MA, Merrick MV, European Journal of Gastroenterology & Hepatology (1996)
  3. 3.Bile acid diarrhoea: pathophysiology and treatment - Walters JR, Alimentary Pharmacology & Therapeutics (2014)
  4. 4.Bile acid malabsorption in IBS-D: knowledge gaps and future directions - Camilleri M, Nature Reviews Gastroenterology & Hepatology (2020)
  5. 5.Review article: the investigation of diarrhoea - Merrick MV, Eastwood MA, Ford MJ, Alimentary Pharmacology & Therapeutics (2012)
  6. 6.British Society of Gastroenterology guidelines on the management of irritable bowel syndrome - Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al., Gut (2021)
  7. 7.Bile acid malabsorption in patients with diarrhoea-predominant irritable bowel syndrome: a systematic review and meta-analysis - Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD, Neurogastroenterology & Motility (2015)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.